Evaluation of irritation potential ofMeela Hair care Herbal Oil throughdermatological Evaluation by singleocclusive patch test on Healthy adult humanvolunteers
Trial Snapshot
- Phase
- Phase 2/3
- Status
- Completed
- Sponsor
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Evaluation of mean scores of
Study Overview
Brief Summary
24 adult healthy subjects will be selected for the study. The subjects selected for this study will be healthy females and males, aged between 18 and 55 years old. in which 12 will be female and 12 will be male subjects.The entire study procedure, patch application, patch reading and grading is detailed in the protocol and followed as per protocol. The patch applied to contain Finn’s chamber within which 2 drops of the test product will be filled in separate’s chambers.The patch is applied on the back or shoulder area of the subjects and will be in contact with the skin for 24 hours. If the subject experiences any allergic reactions, the patch can be removed within 24 hours and reported to Investigator immediately. The mean scores of erythema/dryness, wrinkles, oedema mean irritation index will be calculated on day 1,2,3 and 8.
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Open Label
Eligibility Criteria
- Ages
- 18.00 Year(s) to 55.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Healthy subjects with healthy skin on the studied anatomic unit (free of eczema, wounds & any other inflammatory scar)
- •Age group of 18 to 55 years, 12 male and 12 female subjects.
- •Compliance with the study procedures involved.
Exclusion Criteria
- •Exclusion criteria:
- •Pregnant and lactating women
- •Subjects with any other skin disorders.
- •Use of any other topical agents for any skin related conditions (at the site of application of patch) during the past 30 days.
Outcomes
Primary Outcomes
Evaluation of mean scores of
Time Frame: Day 1,2,3 and 8
Erythema/dryness/wrinkles, Oedema and Mean irritation index
Time Frame: Day 1,2,3 and 8
Irritation Index
Time Frame: Day 1,2,3 and 8
Secondary Outcomes
- occurrence of any adverse effects(Day 1,2,3 and 8)